10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates

分组1 - 10x Genomics reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.30 per share a year ago, resulting in an earnings surprise of +18.52% [1] - The company achieved revenues of $149 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.64%, although this represents a decline from year-ago revenues of $151.65 million [2] - Over the last four quarters, 10x Genomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] 分组2 - The stock has underperformed the market, losing about 6.1% since the beginning of the year, while the S&P 500 has gained 15.6% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates of -$0.23 for the coming quarter and -$0.52 for the current fiscal year, alongside revenues of $151.08 million and $620.66 million respectively [7] - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable industry outlook [8]